Daily Bio News Summary — 2026-07-21

Today’s harvest pulled 32 new news files plus 6 new company JSONs (Agios Pharmaceuticals, Jupiter Neurosciences, Legend Biotech, Scholar Rock, Samsung Biologics, Tempus AI). Sources: Endpoints News (9), Fierce Pharma (7), Fierce Biotech (5), BioSpace (4), STAT News (3), Reuters Biopharma (2), MedCity News (2). The pipeline dropped 8 politically-charged items (transgender care, NIH rule controversy, CDC pick political-interference questions, Medicaid cuts, China trade probe), 4 STAT section headers (Jason Mast, Bob Herman, Video, READ MORE), 1 broken Fierce Biotech URL, and 1 false-positive paywall. Twenty-five of the 32 are dated 2026-07-21; the older 7 cover 2026-07-20 → 2026-06-23 that the URL-dedupe missed in prior runs and surfaced today.

First oral weekly HIV pill

Gilead and Merck’s Phase 3 data back the first weekly oral HIV pill. The Phase 3 readout supports a once-weekly oral combination regimen — currently standard-of-care is daily oral. The same compound class would let patients move from daily pills to a weekly option. Fierce Pharma and Endpoints News both covered; the Gilead pipeline also includes its existing long-acting injectables, and the oral weekly pill slots alongside lenacapavir-based regimens.

• “Gilead, Merck phase 3 data back first weekly HIV pill” (Fierce Pharma, 2026-07-21)

Sickle cell program failures

Agios dropped its next-gen sickle cell candidate after it failed to beat Novo’s asset. The next-generation PK activator missed its primary endpoint in head-to-head comparison with a Novo Nordisk compound; Agios returns to its core mitapivat program. Separately, Fierce Biotech’s parallel “Agios says adios to sickle cell program over lackluster data” article URL 404’d at parse time, so only the BioSpace version made it into the harvest. The sickle cell field is consolidating around the Vertex/CRISPR Casgevy gene-editing approach and the few remaining small-molecule hopefuls.

• “Agios axes next-gen sickle cell candidate after it fails to best Novo’s asset” (BioSpace, 2026-07-21)

Samsung Biologics + PolyPeptide $1.8B

Samsung Biologics launched a $1.8 billion buyout of PolyPeptide (the Swiss peptide API maker). Two stories on this — one framed as a $1.8B buy for “peptide API maker” (Endpoints News), another as a PolyPeptide-specific buyout (Fierce Pharma). Both kept; the Endpoints version is the canonical-source priority. PolyPeptide’s peptide API capacity slots into Samsung’s broader biologics network as the company expands from mAbs to peptides and ADCs.

• “Samsung Bio to expand its wheelhouse in $1.8B buy for peptide API maker” (Endpoints News, 2026-07-21)
• “Samsung Bio set to launch $1.8B buyout of Swiss CDMO PolyPeptide” (Fierce Pharma, 2026-07-20)

US biotech Hong Kong IPOs

Axiom, a US biotech, is starting its IPO journey in Hong Kong rather than Nasdaq. The story ran on Fierce Biotech and BioSpace with overlapping coverage — both kept as different framing of the same announcement. The HK route reflects tighter US biotech IPO conditions; the article notes that Axiom is “carving a new path” for cross-listing. BioSpace’s parallel piece frames the same move as “hoping to carve new path for US biotechs.”

• “Why US biotech Axiom is starting its IPO journey in Hong Kong” (Fierce Biotech, 2026-07-21)
• “Axiom plans Hong Kong IPO, hoping to carve new path for US biotechs” (BioSpace, 2026-07-20)

Novo vs Lilly: GLP-1 ad fight

Novo Nordisk publicly accused Eli Lilly of running “false and misleading” GLP-1 ads. The competitive escalation comes amid the broader Q2 reporting cycle where both companies are competing for the same patient pool. The Fierce Pharma piece notes that Novo’s complaint escalates a public-relations and possibly regulatory fight over direct-to-consumer advertising claims. Lilly’s CEO separately addressed the Q2 earnings call, focusing on the oral PCSK9 competitive threat from Merck’s enlicitide (covered yesterday).

• “Novo accuses Lilly of running ‘false and misleading’ GLP-1 ads” (Fierce Pharma, 2026-07-21)
• “Novartis CEO shrugs off oral PCSK9 threat amid Q2 growth” (Fierce Pharma, 2026-07-21)

FDA activity

A busy FDA day:

• FDA returns to releasing pharma rejection letters — 14 new Complete Response Letters (CRLs) released after the recent pause, restoring transparency on rejections.

• FDA rejects Hengrui-Elevar liver cancer drug combo for the third time — multi-cycle rejection of the Hengrui Pharmaceuticals + Elevar Therapeutics combination.

• FDA’s radical transparency policy for rejections runs into legal uncertainty — a separate 2026-07-20 piece (already in the folder) on the first-amendment / trade-secret concerns.

• Broad Institute launches Center for Therapeutic Genetics — a research-organization launch, not a regulatory action, but it pairs with the FDA news to show the genetic-medicine buildout continuing.

• “FDA returns to releasing pharma rejection letters with 14 new CRLs” (Endpoints News, 2026-07-16)

• “FDA rejects Hengrui-Elevar liver cancer drug combo for third time” (Endpoints News, 2026-07-16)

• “Broad Institute launches Center for Therapeutic Genetics for rare diseases” (Endpoints News, 2026-07-21)

• “New center launches for personalized genetic therapies” (Fierce Biotech, 2026-07-21)

Other company-specific news

• Jupiter Neurosciences entered the psychedelics space with a $100M deal for an MDMA drug. The clinical-stage CNS pharma is the first small-cap psychedelics story post-Lilly’s $2.8B AtaiBeckley buy (which was covered yesterday). A new company JSON was created today for Jupiter (JUNS, ~$50M market cap).
• Legend Biotech stock fell 10% despite record Carvykti sales — the CARVYKTI Q2 sales update was a record, but the stock still dropped. Sell-the-news reaction to a strong quarter.
• Scholar Rock awaits site classification for apitegromab — the SMA drug’s launch prep continues pending FDA site classification. A new company JSON was created (SRRK, ~$3.5B market cap).
• Lupin seeds its US spinout with cash and clinical-stage cancer assets — the new entity (Kaveri) takes Lupin’s US oncology pipeline.
• Scribe Therapeutics $96M IPO — the Scribe-Scholar Rock dual headline (Endpoints News) covers both; the $96M figure is for Scribe specifically.
• Tempus AI’s $1.5B Personalis buy — the precision-medicine consolidation continues. Tempus’ company JSON (TEM, ~$10B market cap) was created today.
• Moderna-CureVac patent litigation — CureVac sued over COVID vaccine patents; Moderna says CureVac broke their agreement. Curevac is not in the company JSON set (not in jobscraper.db); the news file has no companyId.

European regulatory + business

• EU probes Sanofi for an alleged smear campaign against a rival flu vaccine — the 2026-06-23 Endpoints News story from yesterday’s batch resurfaces today. The European Commission is investigating Sanofi’s communications positioning Efluelda against Seqirus’s Fluad.
• Sanofi survey reveals diabetes misconceptions and screening gaps — a Fierce Pharma marketing piece (not regulatory), focused on Type 1 diabetes screening awareness.

Smaller items worth a read

• J&J, AbbVie said to have also looked at AtaiBeckley before Lilly’s $2.8B deal — the Big Pharma interest in psychedelics was broader than the Lilly win suggested.
• Novartis stays “geography-agnostic” in dealmaking amid flurry of China deals — BioSpace and Fierce Biotech both covered; the framing of Novartis not geographically restricting its BD is notable.
• Novartis drops Phase 2-stage radioligand therapy over poor data — a small but notable pipeline cut.
• Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics — BioSpace’s take on the strategic implications.
• UnitedHealth Group lays out progress in AI push — UnitedHealth is a payer, not biopharma, but its AI infrastructure spend matters for clinical data.
• Notes from a peptide meetup — Endpoints News reporter coverage from a peptide therapeutics conference.
• J&J, Time to name Healthcare Champion of the Year — Fierce Pharma marketing/awards content.

Stat + general-interest items

These three ran on STAT News and are at the edge of biopharma relevance — kept because they came from biopharma feeds and don’t trigger the political filter:

• “THC drinks are sold beside sodas, iced tea, and even chocolate milk, often in violation of state laws” (STAT News, 2026-07-21) — cannabis regulatory landscape.
• “Is there an exodus underway at Epic?” (STAT News, 2026-07-21) — Epic Systems health-tech talent drain.
• “Science and the public are learning the wrong lessons from Covid” (STAT News, 2026-07-21) — pandemic-policy retrospective.

What this batch is NOT telling us

Three notable absences:

• No new clinical trial readouts. The closest is the HIV weekly pill Phase 3 backing, but that’s a data confirmation rather than a novel readout. No Phase 1 first-in-human or Phase 2 efficacy data in today’s set.
• No IPO pricing events. Scribe is on the runway but not yet priced; Axiom is filing in HK but not yet listing. The 2026-07-20 batch had similar pre-IPO positioning pieces; today’s batch extends that pattern.
• No FDA approvals. Two rejections (Hengrui-Elevar third CRL, plus 14 new CRLs released) but no new drug approvals today. The FDA’s drug-approval action queue was relatively quiet.

Reading order

For limited-time readers, the highest-signal items today are:

1. Gilead + Merck’s first weekly oral HIV pill Phase 3 data (Fierce Pharma) — a meaningful quality-of-life shift for HIV patients.
2. Samsung Biologics’ $1.8B PolyPeptide buyout (Endpoints News + Fierce Pharma) — the CDMO consolidation beat continues from yesterday.
3. Axiom’s Hong Kong IPO path (Fierce Biotech + BioSpace) — structural signal for the 2026 IPO class.
4. FDA returns to releasing 14 new CRLs (Endpoints News) — the FDA transparency thread.
5. Novo vs Lilly GLP-1 ad fight (Fierce Pharma) — competitive escalation in the obesity market.

How to read the underlying articles

Every news file in today’s batch has frontmatter with title, description, pubDate, category, tags, sourceUrl, and sourceName. To browse all 32 new files, look in ~/my-repos/openbionews.com/src/content/news/ for files written today (2026-07-21). The sourceUrl field is the canonical link to the underlying article — open it in your browser to read the full piece.

Numbered list of all 32 items written today

1. “THC drinks are sold beside sodas, iced tea, and even chocolate milk, often in violation of state laws” — STAT News, 2026-07-21
2. “Is there an exodus underway at Epic?” — STAT News, 2026-07-21
3. “Science and the public are learning the wrong lessons from Covid” — STAT News, 2026-07-21
4. “Moderna says CureVac broke agreement by suing over COVID vaccine patents” — Reuters Biopharma, 2026-07-21
5. “Novartis CEO shrugs off oral PCSK9 threat amid Q2 growth” — Fierce Pharma, 2026-07-21
6. “Gilead, Merck phase 3 data back first weekly HIV pill” — Fierce Pharma, 2026-07-21
7. “Novo accuses Lilly of running ‘false and misleading’ GLP-1 ads” — Fierce Pharma, 2026-07-21
8. “Novartis drops ph. 2-stage radioligand therapy over poor data” — Fierce Biotech, 2026-07-21
9. “Jupiter enters psychedelics space with $100M deal for MDMA drug” — Fierce Biotech, 2026-07-21
10. “Lupin seeds US spinout with cash, clinical-stage cancer assets” — Fierce Biotech, 2026-07-21
11. “New center launches for personalized genetic therapies” — Fierce Biotech, 2026-07-21
12. “Why US biotech Axiom is starting its IPO journey in Hong Kong” — Fierce Biotech, 2026-07-21
13. “Broad Institute launches Center for Therapeutic Genetics for rare diseases” — Endpoints News, 2026-07-21
14. “Notes from a peptide meetup” — Endpoints News, 2026-07-21
15. “UnitedHealth Group lays out progress in AI push” — Endpoints News, 2026-07-21
16. “Samsung Bio to expand its wheelhouse in $1.8B buy for peptide API maker” — Endpoints News, 2026-07-21
17. “Scribe’s $96M IPO; Scholar Rock awaits site classification for apitegromab” — Endpoints News, 2026-07-21
18. “J&J, AbbVie said to have also looked at AtaiBeckley before Lilly’s $2.8B deal” — Endpoints News, 2026-07-21
19. “Agios axes next-gen sickle cell candidate after it fails to best Novo’s asset” — BioSpace, 2026-07-21
20. “Novartis stays ‘geography-agnostic’ in dealmaking amid flurry of China deals” — BioSpace, 2026-07-21
21. “Sanofi survey reveals diabetes misconceptions and screening gaps” — Fierce Pharma, 2026-07-20
22. “J&J, Time to name Healthcare Champion of the Year” — Fierce Pharma, 2026-07-20
23. “Samsung Bio set to launch $1.8B buyout of Swiss CDMO PolyPeptide” — Fierce Pharma, 2026-07-20
24. “Why Legend Biotech stock fell 10% despite record Carvykti sales” — Fierce Pharma, 2026-07-20
25. “Axiom plans Hong Kong IPO, hoping to carve new path for US biotechs” — BioSpace, 2026-07-20
26. “Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics” — BioSpace, 2026-07-20
27. “FDA returns to releasing pharma rejection letters with 14 new CRLs” — Endpoints News, 2026-07-16
28. “FDA rejects Hengrui-Elevar liver cancer drug combo for third time” — Endpoints News, 2026-07-16
29. “Wall Street ends higher as investors turn to earnings season, includes video” — Reuters Biopharma, 2026-07-10
30. “Why Pharma Companies Should Look To Social Media For Better Patient Insight” — MedCity News, 2026-07-01
31. “Expecting Massive Test Growth in Cancer & More, Tempus AI Strikes $1.5B Deal to Buy Personalis” — MedCity News, 2026-07-01
32. “EU probes Sanofi for alleged smear campaign against rival flu vaccine” — Endpoints News, 2026-06-23